01

Lebrikizumab Shows Rapid Gains in Hand and Foot Atopic Dermatitis

Lilly's Phase 3b data show EBGLYSS (lebrikizumab-lbkz) rapidly improved skin clearance, itch, pain, and patient satisfaction in moderate-to-severe hand and foot atopic dermatitis.